StockData
Accustem Sciences Inc. logo

Accustem Sciences Inc. (ACUT) stock

ACUTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$0.15+0.00 (0.00%)

Close on Oct 16, 2026Market cap $2.37MP/E –Yield –

Accustem Sciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Accustem Sciences's operating income for the twelve months ending Jun 30, 2026 was -$1.65M. For fiscal 2025 it was -$1.76M. The highest annual figure on record is -$670.61K in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$1.76M–
FY2024Dec 31, 2024-$1.51M–
FY2023Dec 31, 2023-$2.05M–
FY2022Dec 31, 2022-$3.75M–
FY2021Dec 31, 2021-$670.61K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$252.57K–
Q1 FY2026Mar 31, 2026-$485.88K–
Q4 FY2025Dec 31, 2025-$514.39K–
Q3 FY2025Sep 30, 2025-$399.90K–
Q2 FY2025Jun 30, 2025-$401.40K–
Q1 FY2025Mar 31, 2025-$440.41K–
Q4 FY2024Dec 31, 2024-$372.10K–
Q3 FY2024Sep 30, 2024-$328.17K–
Q2 FY2024Jun 30, 2024-$278.23K–
Q1 FY2024Mar 31, 2024-$526.60K–
Q4 FY2023Dec 31, 2023-$246.04K–
Q3 FY2023Sep 30, 2023-$598.53K–
Q2 FY2023Jun 30, 2023-$372.76K–
Q1 FY2023Mar 31, 2023-$833.34K–
Q4 FY2022Dec 31, 2022-$978.53K–
Q3 FY2022Sep 30, 2022-$899.13K–
Q2 FY2022Jun 30, 2022-$1.08M–
Q1 FY2022Mar 31, 2022-$790.53K–
Q4 FY2021Dec 31, 2021-$543.48K–
Q3 FY2021Sep 30, 2021-$62.72K–
Q2 FY2021Jun 30, 2021-$50.54K–
Q1 FY2021Mar 31, 2021-$13.87K–

More Accustem Sciences figures

See a number that looks wrong?